LA CROSSE, Wis. — Mayo Clinic Health System in La Crosse has provided 1,000 infusions for patients with COVID-19 with monoclonal antibody treatments and remdesivir since November 2020.
The Food and Drug Administration authorized using bamlanivimab and casirivimab-imdevimab late last year to treat confirmed COVID-19 infection in patients who have mild or moderate symptoms, and were at a high-risk of disease progression and hospitalization. The treatments are given to outpatients at infusion centers in La Crosse and Mayo Clinic locations across the Midwest.
Patients recently diagnosed with COVID-19 who are not hospitalized are automatically reviewed daily to see if they meet criteria for infusion. Patients who meet criteria are contacted and receive their infusion in the state where they live at the location that's closest to their home.
Patients receive one dose of this treatment through outpatient IV infusion. Treatments last around 2½ hours. Treatments don't metabolize in the kidneys or liver, and they are not expected to interfere with other patient medications.
The COVID-19 Outpatient Therapy Center supports patients who are positive for COVID-19, and who meet specific criteria and may benefit from COVID-19 therapeutics, including:
- Monoclonal antibodies (casirivimab and imdevimab)
Mayo Clinic Health System in La Crosse participated in a study regarding monoclonal antibody therapies published in the Journal of Primary Care & Community Health. Results showed that despite having more comorbidities (one or more additional conditions) patients who accepted monoclonal antibody treatments had a lower rate of hospitalization, compared to patients who declined treatment. Several social and cultural factors were associated with the decision to decline therapy, including race, language, ethnicity and lack of social support.
Press ContactRick Thiesse